AbbVie (NYSE: ABBV) and Alpine Immune Sciences (SWX: ALPN) have made the decision to prematurely cease enrollment in a Phase II trial for the T-cell stimulatory pathways inhibitor acazicolcept in systemic lupus erythematosus (SEL). This move allows for an early assessment of the trial data and enables Alpine to redirect its development resources towards the autoimmune cytopenias candidate, povetacicept.
The US companies have subsequently amended the terms of their collaboration agreement to accommodate a final analysis of the study by the end of 2024. Additionally, the agreement includes a 25% reduction in potential milestone payments and royalties if AbbVie opts to in-license the molecule for a revised fee of USD 10 million.- Flcube.com
